Harvard Bioscience will move Holliston MA manufacturing out of state
In what it calls a "strategic consolidation of manufacturing operations," Harvard Bioscience Inc. said it's closing its manufacturing facility on October Hill Road in Holliston.
In a press release, the publicly traded company , which makes products used in pre-clinical drug testing, said on Thursday, Jan. 29, that it was moving its manufacturing operations to Minneapolis by the first quarter of 2027. The Holliston facility, which includes the company's corporate headquarters, will remain operational in the meantime.
Harvard Bioscience added that some operations will be relocated to facilities in Germany, Sweden and the United Kingdom.
In a statement, Harvard Bioscience CEO John Duke said the move represents "a meaningful step forward in simplifying our manufacturing footprint and strengthening our operating model."
Earlier: Curia Global says it will close Burlington facility, lay off 81 workers
The company said it expects to achieve about $3 million in cost savings in 2027, and about $4 million annually going forward.
It's not yet clear how many workers will lose their jobs in Holliston. Harvard Bioscience is listed as having 330 total employees in its Yahoo Finance profile but it's unknown how many of them work locally.
Several other plant closures announced in Mass.
News of Harvard Bioscience's Holliston plant closure comes on the heels of several other recent announcements, including Panera Bread and Thermo Fisher Scientific in Franklin; Curia Global in Burlington ; and even the Cape Cod Potato Chip plant in Hyannis .
More: How will Gov. Healey's new budget impact your wallet? Taxes, tax credits?
Paul Diego Craney, executive director of the Massachusetts Fiscal Alliance, a nonprofit that advocates for fiscal responsibility, transparency, and accountability in state government , blamed the negative employment news on Massachusetts' high cost of living and tax policy.
"Beacon Hill keeps telling residents the economy is strong, but workers keep losing their jobs and communities keep losing employers," Craney said in a statement. "You cannot tax, regulate and mandate your way to prosperity. At some point, reality catches up."
Founded in 1901, Harvard Bioscience's customers include academic research labs, and pharmaceutical and biotech companies.
Harvard Bioscience posted 2024 revenues of $94.13 million, down about 16% from the $112.25 million reported the year before. It hasn't yet reported 2025 financial results.
Shares of Harvard Bioscience closed Monday at 50 cents per share on the Nasdaq. As recently as May 2023, they were trading above $6.
This article originally appeared on MetroWest Daily News: Harvard Bioscience says it will close Holliston manufacturing facility
